May 10, 2019 - Ten iuvo employees volunteered at an Epilepsy Pralid Individualized Residential Alternative (IRA) home yesterday as part of the Rochester Day of Caring event.
Wednesday, April 17, 2019 - The air was tense as the inaugural iuvo Chili Cook-off to Support the United Way got under way in the iuvo Canteen at high noon-ish on Wednesday. The contestants had been preparing for, well, at least 24 hours, for this challenge.
iuvo will be teaming up with R&Q for a webinar on Biocompatibility: EU MDR and the Changing Regulatory Landscape. The webinar is March 26, 2019, from 1-2pm ET. The slides, webinar recording, and Q&A will be made available to registrants after the webinar.
On Friday, March 8, 2019, Dr. Mary Richardson and Dr. Kathleen Krenzer from iuvo's toxicology department lectured and conducted a workshop on ISO-10993 Biocompatibility testing at the University of Rochester.
March 4, 2019 – Several members of the iuvo BioScience toxicology team co-authored a paper entitled Suitability of Long-Term Frozen Rat Blood Samples for the Interrogation of Pig-a Gene Mutation by Flow Cytometry.
The International Standards Organisation (ISO) recently published a new technical standard, ISO/TS 21726:2019 Biological evaluation of medical devices – Application of the threshold of toxicological concern (TTC) for assessing biocompatibility of medical device constituents.
On January 14, 2019, the FDA announced recognition (partial) of ISO 10993-1:2018 Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process.
January 28, 2019 - iuvo Chief Scientific Officer and cofounder Dr. Mary Richardson presented at the Sixth Annual Girl Scouts “Women who ROC” seminar series on Friday, January 25, 2019. The event allows local women leaders the opportunity to talk to the scouts about how to build successful careers.
On January 16, 2018, the FDA announced that the Agency will be delaying implementation of parts of its "intended use" rule due to concerns raised by the industry.
Dr. Mary Richardson, iuvo's Chief Scientific Officer, was honored Wednesday evening, January 17, 2018 at a reception with the other finalists for the 2018 ATHENA Awards.
There's frequently a flurry of FDA announcement near the end of the year, and this year was no exception. We wanted to highlight a couple of the more pertinent ones that may be of interest to our customers. The summaries below link to some of the more interesting guidance documents recently released.
Hello, and Happy Holidays!
Welcome to our first edition of “iuvo InSights”, our newly established monthly newsletter. There are a number of very exciting things happening at iuvo BioScience, and across the industry – and each month this newsletter will provide a sampling of the things we are doing, what we are seeing and how we can use these insights to help you…our Customer.
On December 5, 2017, the FDA issued the final version of its guidance document for 3D printed devices. The document "Technical Considerations for Additive Manufactured Medical Devices - Guidance for Industry and Food and Drug Administration Staff" is meant to outline the agency's current thinking about devices made via these processes and will be supplemented by a webinar in January. More information on the webinar is available here.
The FDA has issued a number of guidance documents, primarily focused on the pre-submission process that medical device manufacturers use to improve the likelihood of success of a particular filing.
October 21, 2017 - Members of the iuvo toxicology team co-authored a paper in the October 2017 issue of Comparative Medicine, the international journal of the American Association for Laboratory Animal Science.
As I begin to isolate single bacterial colonies for mutagenicity testing, I couldn’t help but wonder why the bacterial reverse mutation assay has evaded alternate and new technologies for detecting xenobiotic-induced mutation. Of course there is substantial literature and historical data on the salmonella and e. coli strains in wide use today, and there are internationally recognized testing strategies that have been harmonized throughout the past several decades. However, do the highly mutated and compromised bacterial test systems provide any insight into key events along the pathway to mutation? In this day and age, is this the only option to understand the potential for direct DNA reactivity?
On July 11, 2017, the US FDA published a final list of Class II devices exempt from 510(k) Premarket Notification Requirements (82 FR 31976). As mentioned previously here, in an effort to comply with the 21st Century Cures Act of 2016, the Agency originally issued a notice on March 14, 2017 in the Federal Register proposing to exempt a list of Class II devices from the 510(k) premarket notification requirements, with certain limitation (82 FR 13609).
The FDA took the first step on the long road of launching a proposed new laboratory accreditation program this month - the Accreditation Scheme for Conformity Assessment (ASCA).
iuvo's CEO Ben Burton was the feature interview on Launch Team Inc's Beer & Blog Feature today, in an interview with Michele Nichols, Launch Team's President. The Beer & Blog format includes an interview combined with a beer tasting.